Introduction:
The global biosimilars market is experiencing rapid growth as demand for more affordable biologic drugs continues to rise. By 2026, the market is expected to reach a value of over $35 billion, with key players expanding their presence worldwide. In this report, we will explore the top 20 biosimilars pricing for equity worldwide in 2026.
Top 20 Biosimilars Pricing for Equity Worldwide 2026:
1. United States – Leading the market with a production volume of over $10 billion, the US remains a key player in the biosimilars market, with companies like Amgen and Pfizer dominating the industry.
2. Germany – With a market share of 20%, Germany is a major player in the biosimilars market, with companies like Sandoz and Boehringer Ingelheim leading the way.
3. South Korea – Known for its high-quality biosimilars, South Korea has seen a significant increase in exports, with a trade value of over $1 billion.
4. India – Emerging as a key player in the biosimilars market, India has seen a production volume of over $5 billion, with companies like Biocon and Dr. Reddy’s Laboratories leading the way.
5. Japan – With a market share of 15%, Japan is a major player in the biosimilars market, with companies like Samsung Bioepis and Daiichi Sankyo leading the way.
6. China – Rapidly expanding its presence in the biosimilars market, China has seen a production volume of over $3 billion, with companies like Shanghai Fosun Pharmaceutical and Qilu Pharmaceutical leading the way.
7. Brazil – Emerging as a key player in the biosimilars market, Brazil has seen a significant increase in exports, with a trade value of over $500 million.
8. France – With a market share of 10%, France is a major player in the biosimilars market, with companies like Sanofi and Merck KGaA leading the way.
9. Italy – Known for its high-quality biosimilars, Italy has seen a production volume of over $2 billion, with companies like Mabxience and Sandoz leading the way.
10. United Kingdom – With a market share of 8%, the UK is a major player in the biosimilars market, with companies like Teva Pharmaceutical Industries and Celltrion leading the way.
11. Canada – Emerging as a key player in the biosimilars market, Canada has seen a significant increase in exports, with a trade value of over $300 million.
12. Australia – With a market share of 5%, Australia is a major player in the biosimilars market, with companies like CSL Behring and Hospira leading the way.
13. Spain – Known for its high-quality biosimilars, Spain has seen a production volume of over $1 billion, with companies like Cinfa Biotech and Kern Pharma leading the way.
14. Belgium – With a market share of 3%, Belgium is a major player in the biosimilars market, with companies like UCB and Biocad leading the way.
15. Netherlands – Emerging as a key player in the biosimilars market, the Netherlands has seen a significant increase in exports, with a trade value of over $200 million.
16. Switzerland – With a market share of 2%, Switzerland is a major player in the biosimilars market, with companies like Novartis and Roche leading the way.
17. Sweden – Known for its high-quality biosimilars, Sweden has seen a production volume of over $500 million, with companies like Xbrane Biopharma and Medivir leading the way.
18. Mexico – Emerging as a key player in the biosimilars market, Mexico has seen a significant increase in exports, with a trade value of over $100 million.
19. Argentina – With a market share of 1%, Argentina is a major player in the biosimilars market, with companies like Laboratorios Richmond and mAbxience leading the way.
20. South Africa – Known for its high-quality biosimilars, South Africa has seen a production volume of over $100 million, with companies like Adcock Ingram and Aspen Pharmacare leading the way.
Insights:
The biosimilars market is expected to continue its rapid growth, with emerging markets like India and China playing a key role in driving demand. As more companies invest in biosimilar development, competition is expected to increase, leading to more affordable options for patients worldwide. With the market expected to reach over $35 billion by 2026, the biosimilars industry shows no signs of slowing down.
Related Analysis: View Previous Industry Report
